Dezima

Dezima Pharma develops novel compounds to treat cardiovascular disease related to dyslipidemia

Biotech & Life Sciences

Sector

Seed

Stage

Biopharmaceuticals

Model

01Company Overview

Dezima Pharma develops novel compounds to treat cardiovascular disease related to dyslipidemia. Dezima's TULIP study was published in The Lancet in June 2015.

02Backed By1 investor

NSNew Science Ventures→

03Similar Companies

RP

Is this your company? Claim your profile

Riparian Pharmaceuticals

Biotech & Life Sciences

→

LP

Lipigon Pharmaceuticals

Biotech & Life Sciences

→

PP

PhaseBio Pharmaceuticals

Biotech & Life Sciences

→

A

Amarin

Biotech & Life Sciences

→

RP

Rivus Pharmaceuticals

Biotech & Life Sciences

→

04Startup DNA

6

signals

Sectors
Business Model
Technology